Kidney disease is not one condition but more than 60 distinct disorders grouped by which kidney structure fails first: the filtering glomeruli, the tubules and interstitium, the blood vessels, or the collecting system. Each group has its own causes and its own damage mechanism. Glomerular disease is driven mainly by immune complexes and metabolic injury, mostly from diabetes and hypertension. Tubulointerstitial disease is driven by toxins and drugs. Vascular disease is driven by ischemia. Obstructive disease is driven by blocked urine flow. The single largest cause worldwide remains diabetes, followed by hypertension.
How the kidney fails: four compartments, four mechanisms
The kidney holds about 1 million nephrons each. Each nephron pairs a glomerulus, a tuft of capillaries that filters blood under pressure, with a tubule that reabsorbs what the body needs and secretes waste. Damage to any compartment produces a different disease signature.
Glomerular injury leaks protein and red blood cells into urine. Podocytes, the cells that form the filtration slit, carry a negative charge that repels albumin. When that charge barrier fails, albumin spills first. This is why early diabetic kidney disease shows microalbuminuria of 30 to 300 mg per day before total protein rises.
Tubulointerstitial injury impairs concentration and acid handling. Patients lose the ability to concentrate urine, so they urinate 3 to 5 liters a day and still feel thirsty. Serum bicarbonate may fall below 22 mmol/L as the tubules fail to reclaim it.
Vascular injury starves nephrons of oxygen. The kidney receives roughly 20 percent of cardiac output but extracts only about 10 percent of delivered oxygen, so it sits near the hypoxia threshold even at rest. A 20 percent drop in renal blood flow can tip cortical tissue into injury.
Obstruction raises pressure behind the blockage. This pressure transmits backward through the collecting system and compresses the filtration gradient.
In plain terms: the kidney fails in four physical ways, and the cause list follows those four compartments.
The glomerular diseases: immune and metabolic causes
Glomerular disease splits into primary forms, where the kidney is the main target, and secondary forms, where a systemic disease attacks the kidney.
Diabetic nephropathy is the leading cause of kidney failure in most high-income countries. It accounts for 30 to 40 percent of new dialysis starts in the United States. Hyperglycemia glycates proteins and stiffens the afferent arteriole, which raises intraglomerular pressure. That pressure drives mesangial expansion and nodular glomerulosclerosis, first described by Kimmelstiel and Wilson in 1936.
IgA nephropathy is the most common primary glomerulonephritis worldwide. It affects 2.5 per 100,000 people per year in some Asian populations. Galactose-deficient IgA1 triggers immune complexes that deposit in the mesangium.
Membranous nephropathy targets the phospholipase A2 receptor in about 70 to 80 percent of primary cases. It causes nephrotic-range proteinuria, defined as more than 3.5 grams per day.
Focal segmental glomerulosclerosis, or FSGS, scars parts of some glomeruli. It recurs in 30 to 40 percent of kidney transplants in patients with the circulating permeability factor variant.
Minimal change disease causes sudden nephrotic syndrome, mostly in children, with normal light microscopy. Electron microscopy reveals podocyte foot process effacement.
Post-infectious glomerulonephritis follows streptococcal infection by 1 to 3 weeks and is now rare in adults.
Lupus nephritis affects up to 60 percent of adults with systemic lupus erythematosus. It requires biopsy staging from class I to class VI.
Anti-GBM disease, also called Goodpasture disease, attacks the glomerular basement membrane directly. It can cause lung hemorrhage and kidney failure within days.
The tubulointerstitial diseases: drugs, toxins, and infections
Tubulointerstitial nephritis, or TIN, is inflammation of the space between tubules. Drugs cause roughly 70 percent of acute cases.
Proton pump inhibitors rank among the most common culprits. Cohort data associate long-term use with a 20 to 50 percent higher risk of chronic kidney damage. Nonsteroidal anti-inflammatory drugs are another major cause, and they act through two mechanisms: acute TIN and reduced prostaglandin-mediated blood flow.
Antibiotics, especially penicillins and rifampin, trigger allergic TIN with fever, rash, and eosinophilia in about one-third of cases. The classic triad is present in a minority, so absence does not exclude the diagnosis.
Aminoglycosides injure proximal tubules directly. They accumulate in lysosomes and cause dose-dependent toxicity above cumulative exposures.
Analgesic nephropathy from combined phenacetin or mixed analgesics causes papillary necrosis. It declined sharply after phenacetin was withdrawn in the 1980s.
Chronic interstitial nephritis from heavy metals, such as lead and cadmium, produces slowly progressive fibrosis. Lead exposure has been linked to gout and hypertension at blood levels once considered safe.
The vascular diseases: ischemia, sclerosis, and thrombosis
Renal artery stenosis narrows the artery in 1 to 5 percent of hypertensive patients. Atherosclerosis causes 90 percent of cases, and fibromuscular dysplasia causes most of the rest, mostly in women aged 30 to 50.
Hypertensive nephrosclerosis is the second-leading cause of kidney failure in the United States. Chronic pressures above 140/90 mmHg cause arteriolar hyalinosis and global glomerulosclerosis.
Renal vein thrombosis typically occurs in nephrotic syndrome, where urinary loss of antithrombin III raises clot risk. Membranous nephropathy carries the highest risk, at 20 to 40 percent in severe proteinuria.
Atheroembolic disease follows catheter procedures. Cholesterol crystals lodge in small arteries after angiography, and the kidneys are a frequent target.
Sickle cell nephropathy affects up to 30 percent of adults with sickle cell disease. Sickled red cells occlude the vasa recta and cause papillary necrosis.
The cystic and genetic diseases: inheritance and progression
Autosomal dominant polycystic kidney disease, or ADPKD, affects 1 in 400 to 1,000 people. It causes about 5 percent of kidney failure cases. Mutations in PKD1 or PKD2 produce cysts that enlarge the kidney to 3 to 4 times normal size by age 50.
Autosomal recessive polycystic kidney disease occurs in 1 in 20,000 births and often presents in infancy.
Alport syndrome is a collagen IV defect that causes hearing loss and eye abnormalities in about 50 to 80 percent of affected males.
Fabry disease is an X-linked lysosomal storage disorder. It affects about 1 in 40,000 males and causes proteinuria and progressive kidney failure.
Nephronophthisis is a ciliopathy that causes kidney failure in children and young adults. It is the most common genetic cause of kidney failure in the first two decades of life.
The obstructive and infectious diseases: anatomic causes
Obstructive uropathy causes 5 to 10 percent of kidney failure cases. Benign prostatic hyperplasia is the most common cause in men over 60. Stones are the most common cause in younger adults.
Kidney stones affect about 1 in 11 people in the United States. Calcium oxalate stones make up 70 to 80 percent of cases. Struvite stones form from urease-producing bacteria and can grow into staghorn calculi.
Recurrent pyelonephritis scars the kidney over years. More than three episodes per year warrant imaging to exclude obstruction or reflux.
Vesicoureteral reflux affects 1 to 2 percent of children. It causes scarring in a minority, but the risk rises with higher grades.
Neurogenic bladder from spinal cord injury or diabetes causes high-pressure retention that damages the upper tract.
Comparing the major groups: what actually differs
| Disease group | Core mechanism | Typical urine finding | Key lab threshold | Leading causes |
|---|---|---|---|---|
| Glomerular | Immune complex or metabolic injury | Proteinuria, hematuria | Protein > 3.5 g/day (nephrotic) | Diabetes, IgA, lupus |
| Tubulointerstitial | Toxic or allergic inflammation | Sterile pyuria, eosinophils | Creatinine rise > 0.3 mg/dL in 48 hours | Drugs, infections |
| Vascular | Ischemia or thrombosis | Mild proteinuria | Stenosis > 60 percent | Atherosclerosis, hypertension |
| Cystic/genetic | Gene mutation, cyst growth | Variable | Kidney volume > 3x normal | PKD1, PKD2 |
| Obstructive | Pressure backup | Post-void residual > 100 mL | Hydronephrosis on imaging | BPH, stones |
Total kidney failure, defined as eGFR below 15 mL/min per 1.73 m², is the shared endpoint. An eGFR of 60 or above is normal. The 2024 KDIGO guidance stages chronic kidney disease from G1 to G5 using these thresholds. In plain terms: the groups differ in cause, but they converge on the same final pathway of nephron loss.
How kidney disease progresses: a timeline
| Stage | Time course | eGFR (mL/min/1.73 m²) | What happens |
|---|---|---|---|
| Silent injury | 5 to 10 years | 90 or above | No symptoms; damage begins |
| Early CKD | 1 to 3 years | 60 to 89 | Microalbuminuria appears |
| Moderate CKD | 2 to 5 years | 30 to 59 | Blood pressure rises; anemia may start |
| Severe CKD | 1 to 3 years | 15 to 29 | Fatigue, mineral bone disease |
| Kidney failure | 6 to 12 months | Below 15 | Dialysis or transplant needed |
Diabetic kidney disease typically takes 10 to 20 years to reach kidney failure. Hypertensive nephrosclerosis is usually slower. Rapidly progressive glomerulonephritis can destroy the kidney in weeks to months. The timeline difference matters because fast progression demands urgent biopsy.
Non-obvious findings and corrected misconceptions
The first is that creatinine is a late marker. A person can lose 50 percent of kidney function before serum creatinine rises above the upper limit of normal. eGFR formulas correct for this only partly.
The second is that proteinuria predicts outcome better than eGFR in many glomerular diseases. A 50 percent reduction in proteinuria is a validated surrogate endpoint for slower progression.
The third is the obesity paradox in dialysis. Higher body mass index is associated with better survival in dialysis patients, a reversal of the pattern in the general population. The likely explanation is that muscle mass and nutritional reserve protect against dialysis-related catabolism.
The fourth is that nephrotoxic drug injury is often reversible if the trigger is removed within 7 to 14 days. Delayed recognition converts reversible injury into fibrosis.
The fifth is that "kidney failure" and "kidney disease" are not interchangeable. Most people with kidney disease never reach failure.
Red flags that warrant urgent evaluation
- Foamy urine lasting more than a few days, suggesting protein loss
- Blood in urine without pain or infection
- Swelling of the legs, face, or eyelids that is new
- Blood pressure above 140/90 mmHg on repeated readings
- A creatinine rise of 0.3 mg/dL or more within 48 hours
What to actually do
Ask for an eGFR and a urine albumin-to-creatinine ratio at any routine check if you have diabetes, hypertension, or a family history of kidney disease. These two tests cost about USD 30 combined in most US labs and detect disease years before symptoms.
Keep blood pressure below 130/80 mmHg if you have chronic kidney disease. The 2021 KDIGO blood pressure guideline sets this target, and the 2017 ACC/AHA hypertension guideline aligns with it for most adults. Reconcile the targets explicitly: 130/80 mmHg for CKD, 140/90 mmHg for the general population without CKD.
Control blood sugar to an A1c below 7 percent if you have diabetes. Every 1 percent reduction lowers microvascular risk by about 25 percent.
Review your medication list annually. Stop unnecessary NSAIDs and proton pump inhibitors when possible.
Avoid dehydration during illness. Dehydration reduces renal blood flow and concentrates toxins in the tubules.
Limits of the evidence
Cause attribution is often probabilistic, not certain. Many kidney diseases have multiple contributors, and biopsy findings can be nonspecific. Registries undercount early disease because most cases are asymptomatic. Genetic testing identifies a cause in only 10 to 20 percent of adults with unexplained kidney failure. Numbers vary by population and by how disease is defined, so treat any single figure as a range estimate rather than a fixed truth.